CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets
October 11 2006 - 8:00AM
PR Newswire (US)
PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today that it has sent
Solvay Pharmaceuticals, Inc. a notice of termination under the
companies' co-promotion agreement for ACEON(R) (perindopril
erbumine) Tablets. Over the next several weeks, CV Therapeutics
will conclude its promotion of ACEON. There are no financial
commitments for either company related to the termination of the
co-promotion agreement. CV Therapeutics does not expect to
recognize further revenues from ACEON. "We are excited to focus our
promotional efforts on Ranexa, as we continue to see growing
interest in the cardiology community," said Louis G. Lange, M.D.,
Ph.D., chairman and chief executive officer of CV Therapeutics.
About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo
Alto, California, is a biopharmaceutical company focused on
applying molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics' approved product,
Ranexa(R) (ranolazine extended-release tablets) is indicated for
the treatment of chronic angina in patients who have not achieved
an adequate response with other antianginal drugs, and should be
used in combination with amlodipine, beta-blockers or nitrates. CV
Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which
is being developed for potential use as a pharmacologic stress
agent in myocardial perfusion imaging studies and CVT-6883, which
is being developed as a potential treatment for asthma and other
conditions. Regadenoson and CVT-6883 have not been determined by
any regulatory authorities to be safe or effective in humans for
any use. Except for the historical information contained herein,
the matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including
dependence on Ranexa; commercialization of products; market
acceptance of products; product labeling; and other risks detailed
from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.
CV Therapeutics disclaims any intent or obligation to update these
forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: John Bluth, Senior Director of Corporate Communications
and Investor Relations, of CV Therapeutics, Inc., +1-650-384-8850
Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Sep 2023 to Sep 2024